Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

67.08 +0.05 (+0.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
$100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Time For Gilead Sciences-Heavy ETFs?
Gilead Sciences has underperformed the broader market this year by a hefty margin. 
Via Talk Markets
Gilead's Breast Cancer Drug Shows Promise When Combined With Merck's Treatment
Gilead Sciences Inc (NASDAQ: GILD) revealed early data from its open-label, Phase 2 EVOKE-02 study evaluating Trodelvy. 
Via Benzinga
What You Need to Know About Hepatitis C This Recovery Month
(BPT) - Hepatitis C (HCV) is often referred to as the 'silent disease' due to silent symptoms that may not appear until years after exposure. In fact, of the more than 2 million Americans who are... 
Via Brandpoint
Exposures COVID-19
How To Earn $500 A Month From Gilead Sciences Stock
Shares of Gilead Sciences, Inc (NASDAQ: GILD) are trading higher during Friday’s trading session, bolstered by the Bank of America Securities bullish outlook on the stock. 
Via Benzinga
Infectious Disease Player Vir Biotech Has Limited Near Term Upside, Analyst Downgrades
BofA Securities has downgraded Vir Biotechnology Inc (NASDAQ: VIR) to Neutral from Buy with a price target of $14,  
Via Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $9,000 Today
Via Benzinga
Where Gilead Sciences Stands With Analysts
Via Benzinga
(GILD) - Analyzing Gilead Sciences's Short Interest
Via Benzinga
The Unexpected Reason Gilead Just Notched Its Biggest Single-Day Move In A Month
Gilead shares are on the rise amid an unexpected boon for its HIV treatment business. 
Via Investor's Business Daily
Gilead Sciences Shares Trade Higher After Bullish Analyst Upgrades Stock
Shares of Gilead Sciences, Inc. (NASDAQ: GILD) are trading higher into Friday’s trading session after Bank of America Securities upgraded the stock, highlighting an underappreciated growth potential in... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023
Via Benzinga
Adobe To Rally Over 12%? Here Are 10 Other Analyst Forecasts For Friday
B of A Securities cut the price target for DigitalOcean Holdings, Inc. (NYSE: DOCN) from $47 to $25. B of A Securities analyst Wamsi Mohan downgraded the stock from Buy to Underperform. DigitalOcean... 
Via Benzinga
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
Via Benzinga
How Is The Market Feeling About Gilead Sciences?
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Via Benzinga
3 No-Brainer Dividend Stocks to Buy in September
Income investors should really like these biopharma stocks with juicy dividends. 
Via The Motley Fool
Nearing Retirement? These Stocks Will Pay You For Life
These companies are passive income machines. 
Via The Motley Fool
2 High-Yield Dividend Stocks to Buy on the Dip
The market may have been a bit too harsh on these stocks. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
GILD Stock Alert: FDA Approves Gilead Sciences’ Veklury Covid-19 Treatment
Gilead Sciences (GILD) stock is on the move Thursday following additional FDA approval for its Veklury Covid-19 treatment. 
Via InvestorPlace
Exposures COVID-19 Product Safety
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus... 
Via Benzinga
How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30%
Roche provided an update from its study in lung cancer using an anti-TIGIT drug. 
Via Investor's Business Daily
San Francisco Business Times Names Landis Communications Inc. (Landis) the Top 2022 Bay Area Corporate Philanthropist as a Percentage Of Profits
--News Direct-- 
Via News Direct
Topics LGBTQ
Exposures Diversity
Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner
Biotech stocks are in a bear market since the IBB hit $177.37 in 2021 and is down 7.84% over five years. 
Via Talk Markets
FDA Pauses Gilead's Investigational Magrolimab Study In Blood Cancer Patients
FDA has placed a partial clinical hold on Gilead Sciences Inc (NASDAQ: GILD) initiation of new patients in U.S. 
Via Benzinga
Exposures Product Safety
5 Safe Stocks Under $40 to Buy Immediately
Investors are turning away from risky bets and putting their money in safe stocks this week. Here are four names under $40 to buy now. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Autolus Therapeutics' Obe-Cel's Shows Compelling Safety Over Gilead's Drug For Acute Lymphoblastic Leukemia
Truist has raised the price target for Autolus Therapeutics PLC (NASDAQ: AUTL) from $6 to $9  
Via Benzinga
The 3 Best Biotech Stocks to Buy in August
Even as healthcare stocks suffer from post-pandemic fatigue, these three of the best biotech stocks to buy and ride the wave of good news. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.